Department of Pediatrics, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
Department of Pediatric Thoracic and Cardiovascular Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Pediatr Cardiol. 2021 Dec;42(8):1700-1705. doi: 10.1007/s00246-021-02653-7. Epub 2021 Jun 7.
The safety and efficacy of landiolol have not been fully elucidated in pediatric patients. This study aimed to clarify the safety and efficacy of landiolol in a pediatric cohort. We retrospectively assessed the clinical features of 21 pediatric patients who were administered landiolol at our hospital. We also investigated the rates of sinus rhythm conversion and heart rate response. The median patient age was 7 months (interquartile range 1-13 months). The etiology of tachyarrhythmia was junctional ectopic tachycardia in 10 patients (47.6%), atrial tachycardia in 10 patients (47.6%), and ventricular tachycardia in 1 patient (4.8%). Of the 21 children, 18 (85.7%) had congenital heart defects, including 14 (77.8%) in whom a landiolol infusion was performed perioperatively. The landiolol infusion was effective in 18 pediatric patients (85.7%), as measured by the conversion to sinus rhythm or a reduced heart rate. Atrial tachycardia in the perioperative period was terminated in all patients. Of 7 patients with tachyarrhythmias unrelated to the perioperative period, landiolol was effective in 5. No adverse effects were reported in any patient. Landiolol infusion is effective and safe in pediatric patients with tachyarrhythmia of various etiologies, especially those with atrial tachyarrhythmia during the perioperative period.
兰地洛尔在儿科患者中的安全性和疗效尚未完全阐明。本研究旨在阐明兰地洛尔在儿科患者中的安全性和疗效。我们回顾性评估了在我院接受兰地洛尔治疗的 21 例儿科患者的临床特征。我们还调查了窦性心律转复率和心率反应率。中位患者年龄为 7 个月（四分位距 1-13 个月）。心动过速的病因中，交界性异位心动过速 10 例（47.6%），房性心动过速 10 例（47.6%），室性心动过速 1 例（4.8%）。21 例患儿中，18 例（85.7%）存在先天性心脏病，其中 14 例（77.8%）在围手术期使用兰地洛尔。18 例（85.7%）患儿心动过速转复为窦性心律或心率降低，兰地洛尔输注有效。所有围手术期合并房性心动过速的患儿心动过速均终止。7 例非围手术期心动过速患儿中，5 例兰地洛尔有效。患儿均未出现不良反应。兰地洛尔输注对各种病因引起的儿科心动过速患儿有效且安全，尤其是围手术期合并房性心动过速的患儿。
